// App-Quantinova.ai

: Correlation of Fatigue Severity and Psoriasis Severity, and the Treatment Effect of Guselkumab: A Detailed Analysis of SF-36 Vitality Scores From the VOYAGE 2 Study

Researchers

Presenter

  • Bruce Strober

Principal Investigators

  • Yi-hsuan Liu

  • Ya-Wen Yang

  • Megan Miller

  • Daphne Chan

  • Wolf-Henning Boehncke

  • Laura Savage

  • April Armstrong

  • Chenglong Han

Medical Centers

  • Janssen Global Services, LLC, Horsham/Malvern, PA, USA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Scientific Affairs, Horsham, PA

  • University Hospitals and University of Geneva, Geneva, Switzerland

  • University of Leeds, Leeds, UK

  • Keck School of Medicine of University of Southern California, Los Angeles, CA

Locations

  • United States

  • Japan

  • Switzerland

  • United Kingdom

  • Maldives

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved